/

UCB.BR

UCBOpen

198.65+0.75 +0.38%EUR

Brussels · as of Oct 14, 03:52 ET · 15m delay

Open

197.45

Prev close

197.90

Day range

197.45199.15

52-week range

197.45289.50

Volume

9.46K0.04×

Mkt cap

37.88B

P/E ttm

17.04

Fwd P/E

14.38

EPS ttm

11.66

Div yield

0.73%

Earnings

Jul 30, 2026

From 52w high

−31.38%

Price Chart

Yahoo Finance · delayed

UCB.BROct 14, 2026O 197.45H 199.15L 197.45C 198.65−5.25 (−2.57%)Vol 9.46K

SMA 50212.83
SMA 200242.70

1Y change −23.60% since Oct 13, 2025 close549 bars loadedTimes in Europe/BrusselsDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

UCB.BR UCB · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −2.53%
1 month: −5.63%
3 months: −15.72%
6 months: −25.24%
Year to date: −16.74%
1 year: −23.03%

Valuation & ownership

Market cap: 37.88B
Enterprise value: 40.55B
P/E (ttm): 17.04
Forward P/E: 14.38
PEG ratio: 1.07
Price / book: 3.25
Price / sales (ttm): 4.44
EV / EBITDA: 12.92
EPS (ttm): 11.66
EPS (forward): 13.81
Beta (5y monthly): 0.19
Dividend yield: 0.73%
Payout ratio: 12.81%
Shares outstanding: 190.66M
Float: 120.16M
Short % of float: —
Short ratio (days): —
Held by insiders: 36.28%
Held by institutions: 39.49%
Avg volume (3m): 230.91K
50-day average: 213.33
200-day average: 243.18
52-week change: −23.03%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 36.6
vs 50-day SMA: −6.66%
vs 200-day SMA: −18.15%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 2.65%
Realised vol (20d, ann.): 22.0%
From 52-week high: −31.38%
From 52-week low: +0.61%

ANR

Analyst Consensus

19 analysts

Consensus

Buy

1.60 on a 1 (strong buy) – 5 (sell) scale

Mean target

285.00

+43.47% implied

Low 208.00Median 295.00High 340.00

Recommendation trend

Now15 / 5 / 0
1m ago15 / 5 / 0

DES

About UCB

Yahoo Finance profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Sector: Healthcare
Industry: Biotechnology
Employees: 9,000
Headquarters: Brussels, Belgium
Website: ucb.com
Officers

SEAS

Seasonality · UCB.BR

2007–2026 · monthly returns

Strongest month Jul +3.00%Weakest month May −1.31%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	7.0	-1.2	2.5	-10.6	8.9	4.1	-14.9	-3.4	-4.7	-3.1			−16.7%
2025	-2.1	-3.5	-10.4	-1.0	-0.8	4.4	14.1	4.9	17.6	-5.3	8.1	-0.8	+24.1%
2024	10.6	22.0	7.4	8.9	3.3	7.8	11.5	5.9	-1.0	9.1	4.8	3.7	+143.6%
2023	2.5	8.0	1.3	2.4	-3.4	-0.4	-0.8	2.8	-6.4	-10.9	-1.8	16.3	+7.3%
2022	-12.3	11.0	11.0	-0.0	-24.2	-1.9	-5.4	-8.1	1.5	7.3	0.6	-4.2	−26.7%
2021	1.2	-3.6	-1.6	-5.0	-0.7	15.2	3.4	6.2	-0.1	6.5	-6.8	4.4	+18.8%
2020	17.2	0.6	-5.5	5.7	7.7	14.6	5.6	-8.6	-2.5	-12.7	5.7	-5.7	+19.2%
2019	6.1	-2.6	3.9	-7.6	-3.2	6.5	-3.2	-3.8	-2.0	8.5	1.8	-3.6	−0.6%
2018	6.1	-3.0	-2.8	-5.2	7.6	-0.2	9.1	7.3	-1.8	-4.2	0.1	-4.0	+7.7%
2017	4.6	5.5	8.2	-1.6	-12.2	-4.1	2.2	-6.0	4.0	3.8	0.4	5.5	+8.7%
2016	-5.5	-12.9	-1.8	-2.8	-0.6	3.5	4.1	5.2	-6.5	-10.4	-1.6	0.3	−26.8%
2015	9.1	-0.9	-1.5	-4.5	1.2	-1.1	9.4	-4.1	3.4	12.7	7.4	-1.5	+31.7%
2014	-3.0	10.8	-0.1	1.7	-1.0	5.7	11.0	7.4	-2.5	-10.4	-2.0	0.2	+16.7%
2013	-1.6	4.1	12.5	-9.9	-5.8	-2.2	4.7	1.6	2.3	7.6	2.0	9.6	+25.3%
2012	-4.4	-2.5	6.7	9.1	7.5	5.1	2.3	-4.3	9.7	5.2	-3.0	-1.0	+32.9%
2011	1.8	3.1	-0.5	21.7	1.8	-6.6	3.5	-0.2	0.3	-0.6	-2.6	4.7	+26.6%
2010	10.6	0.6	-2.7	-7.8	-7.7	-3.9	-4.3	-9.0	12.9	9.7	-10.6	3.1	−12.1%
2009	4.6	-10.0	1.2	-6.6	13.3	-2.9	1.7	17.0	6.3	0.8	2.0	-1.5	+25.4%
2008	4.7	-3.5	-29.8	26.4	-6.8	-9.3	-6.4	22.2	-7.4	-19.8	17.7	-0.8	−24.9%
2007	-2.1	-4.0	-10.8	0.5	-0.7	0.9	-5.7	-0.1	0.2	-2.1	-19.8	-4.5	−40.3%

UCB.BR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

UCB.BR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About UCB

Seasonality · UCB.BR

Insider Activity · UCB.BR

Congress Trades · UCB.BR

Investors Holding UCB.BR

Investors Holding UCB.BR

Congress Trades · UCB.BR

Insider Activity · UCB.BR

Seasonality · UCB.BR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About UCB

Financial Snapshot

Earnings & Dividends

News